JFL Life Sciences Share Price Today | Stock Price & JFL Life Sciences Share Screener
Track the current JFL Life Sciences share price and stock price live with TickJournal's free stock screener. Check JFL Life Sciences 52-week for the annual price range and momentum. Use the JFL Life Sciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today JFL Life Sciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹131 and net income of ₹7, with EBITDA of ₹12, an operating margin of 12.0% and a profit margin of 5.3%.
JFL Life Sciences Share Price Chart
Track the current stock price of JFL Life Sciences with an interactive chart. Analyse JFLLIFE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete JFL Life Sciences stock quote in one place.
JFL Life Sciences Company Profile - Fundamental Screener
Screen JFL Life Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for JFLLIFE shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE0LA901015.
Company Details
Classification
Identifiers and Leadership
JFL Life Sciences Balance Sheet Screener
Screen JFLLIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹106, up from ₹72 in 2025.
Latest statistics put total assets at ₹106 and shareholder funds at ₹46, with a leverage ratio of 0.22.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
Assets |
||||||||
| Total Assets | 106 | 72 | 57 | 49 | 48 | 29 | 24 | 16 |
| Current Assets | 92 | 60 | 44 | 41 | 39 | 21 | 18 | 14 |
| Fixed Assets | 15 | 12 | 13 | 7 | 7 | 7 | 5 | 3 |
Liabilities |
||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 7 | 1 | 1 | 2 | 9 | 8 | 1 | 3 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||
| Total Equity | 46 | 40 | 36 | 32 | 11 | 7 | 5 | 5 |
| Share Capital | 33 | 33 | 11 | 11 | 8 | 1 | 0 | 0 |
| Reserves & Surplus | 13 | 7 | 25 | 21 | 3 | 6 | 5 | 5 |
JFL Life Sciences Income Statement Screener - Profit & Revenue Analysis
Screen JFL Life Sciences income statement and profit fundamentals. Analyze JFLLIFE quarterly results. JFL Life Sciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹131 and net profit was ₹7, equal to earnings per unit of ₹2.10, at an operating margin of 12%.
In that period expenses were ₹119, interest cost ₹2 and tax ₹2. The next period listed, 2026-March, shows revenue of ₹131 and net profit of ₹6.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||
| Revenue | 131 | 131 | 82 | 47 | 45 | 35 | 33 | 30 | 32 |
| Expenses | 119 | 120 | 74 | 42 | 39 | 28 | 31 | 28 | 31 |
Operating Costs and Margins | |||||||||
| EBITDA | 12 | 12 | 8 | 5 | 6 | 6 | 2 | 2 | 1 |
| Operating Profit % | 12.00% | 9.00% | 10.00% | 10.00% | 9.00% | 16.00% | 7.00% | 6.00% | 4.00% |
| Depreciation | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
Profit and Earnings | |||||||||
| Profit Before Tax | 9 | 9 | 6 | 4 | 4 | 4 | 1 | 1 | 0 |
| Tax | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 |
| Net Profit | 7 | 6 | 4 | 3 | 3 | 3 | 1 | 0 | 0 |
| EPS | 2.10 | 1.94 | 1.26 | 1.00 | 2.90 | 4.12 | 0.89 | 0.66 | 0.59 |
JFL Life Sciences Cash Flow Screener - Liquidity Fundamentals
Screen JFLLIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹4.
Over the same period, investing activities provided ₹0 and financing activities provided ₹4.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | |||||||
| Operating Activities | -4 | 8 | -9 | 2 | -6 | 3 | -3 |
| Investing Activities | 0 | -6 | 1 | -1 | -2 | -3 | -1 |
Financing and Net Cash | |||||||
| Financing Activities | 4 | -2 | 8 | -2 | 7 | 0 | 4 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JFL Life Sciences Shareholding Pattern Screener
See JFL Life Sciences shareholding pattern with promoter, FII, and DII holdings. Check JFL Life Sciences promoter holding and ownership changes for JFLLIFE on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 67.47%, foreign institutions 0.00%, domestic institutions 0.00% and the public 28.31%, spread across 943 shareholders.
The shareholder count was 943 in 2026-Jun, compared with 971 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Sept | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 28.31% | 28.49% | 28.54% | 28.88% | 28.95% | 28.77% | 28.37% | 28.06% |
| Other Holding | 4.22% | 4.04% | 3.99% | 3.66% | 3.58% | 3.76% | 4.16% | 4.47% |
| Shareholder Count | 943 | 971 | 991 | 998 | 1,022 | 997 | 966 | 825 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by JFL Life Sciences. JFL Life Sciences dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.25 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.25 | 1.43% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
JFL Life Sciences Stock Index Membership - Nifty & Sensex
See which indices include JFL Life Sciences stock. Check JFLLIFE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
JFL Life Sciences Market Events Screener - Corporate Actions
Get JFL Life Sciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check JFL Life Sciences stock events that may affect JFLLIFE share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 10, 2026, with a record date of August 10, 2026.
It is followed by Quarterly Result Announcement dated May 29, 2026 and Quarterly Result Announcement dated January 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-10 | 2026-08-10 | Quarterly Result Announcement | NA | 3.02% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | -4.92% |
| 2026-01-29 | 2026-01-29 | Quarterly Result Announcement | NA | -2.43% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -2.17% |
| 2025-10-28 | 2025-10-28 | Extraordinary General Meeting | NA | 1.16% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | 1.42% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 20.85% |
| 2025-04-08 | 2025-04-08 | Quarterly Result Announcement | NA | 4.52% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 26.39% |
| 2024-09-24 | 2024-09-24 | Bonus | 2:1 | 1.06% |
| 2024-09-23 | 2024-09-23 | Annual General Meeting | NA | 9.54% |
| 2024-09-13 | 2024-09-16 | Dividend | ₹ 0.25 /share | 4.68% |
JFL Life Sciences Competitors Screener - Peer Stocks Comparison
Screen JFLLIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 439,006 | 36.83 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 248,253 | 86.00 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 183,984 | 86.72 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 115,242 | 25.96 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 109,925 | 33.29 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 106,760 | 98.39 | 6,868 | 22.01% | 890 | 58.00 |
| Dr Reddys Laboratories | 102,691 | 32.77 | 35,059 | 3.90% | 4,158 | 69.59 |
| Mankind Pharma | 101,865 | 50.84 | 14,636 | 14.85% | 1,938 | 64.24 |
| Aurobindo Pharma | 96,416 | 26.41 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,479 | 16.97 | 29,039 | 26.75% | 5,356 | 34.02 |
JFL Life Sciences Company Announcements - News & Reports Screener
Screen JFLLIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
Frequently Asked Questions
How is the company valued right now?
The P/E ratio is 4.88 and the P/B ratio is 0.72, with earnings per unit of ₹1.94. Market capitalisation stands at ₹65.99 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on October 6, 2026. This page covers 8 balance sheet periods, 9 income statement periods, 7 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.